Innovation and Inequality: A Randomized Experiment with Physicians

How to cite

Alsan, Marcella; Durvasula, Maya; Gupta, Harsh; Williams, Heidi. 2022. "Innovation and Inequality: A Randomized Experiment with Physicians." AEA RCT Registry. AEARCTR-0008959. https://doi.org/10.1257/rct.8959-1.0

Download: BibTeX · RIS — for reference managers without a browser translator. Zotero and most others pick up this page's citation metadata directly.

Marcella Alsan* , Maya Durvasula , Harsh Gupta , Heidi Williams

* Primary investigator

Registry ID
AEARCTR-0008959
DOI
https://doi.org/10.1257/rct.8959-1.0
First registered
Last updated
Status
In development
Trial dates
2022-03-01 – 2023-03-01
Countries
Private
Registry record
http://www.socialscienceregistry.org/trials/8959

Abstract

Randomized clinical trials play a critical role in generating knowledge about the safety and efficacy of new pharmaceuticals. However, many clinical trials are not representative of the patient population the resulting pharmaceuticals would serve. In a randomized experiment, we seek to understand how clinical trial diversity affects physician assessments of trial relevance for specific patient sub-groups and willingness to prescribe pharmaceuticals.

Intervention

We will present primary care physicians with hypothetical profiles of clinical trials that vary in the demographic diversity of their subjects as well as in drug efficacy. Some of the profiles will be demographically representative of the U.S. population or the physician's patient population, whereas others will be less so.

Experimental design

We will invite 10,000 primary care physicians to participate in the survey by randomly sampling physicians from a large database of physician contact information and emailing those selected. Those who start the survey will first be asked questions about their clinical practice, including their qualifications and the demographics of their patient population. They will then view 8-10 profiles of hypothetical drug trials in which the demographic diversity of the clinical trial (such as share Black of participants) and drug efficacy as found by the trial will be cross-randomized. For each profile, participants will rate how relevant the trial's findings are for their patient population as well as how likely they are to prescribe the drug to patients in their care.

Design details

Randomization method
Randomization will be done in Qualtrics.
Randomization unit
The unit of randomization will be the individual.
Clusters
N/A
Observations
10,000 physicians will be invited to participate, of whom about 250 are expected to complete the survey. This number of participants would lead to approximately 2000-2500 profile-physician observations as each physician will rate 8-10 profiles.
Arms
Physicians will see drug trial profiles that will vary in demographic diversity and efficacy along approximately uniform distributions (although low diversity shares such as 0% Black may be over-sampled); hence there are no discrete treatment arms per se.
Primary outcomes
Assessment of study relevance for patient population and willingness to prescribe drug studied in trial to patient population

Cited by

No citation data available for this registration yet.

Keywords